Beactica
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Virdings Allé 2, Uppsala, Uppsala, 754 5...Phone Number
+46 18560880Website
www.beactica.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Beactica
Beactica Therapeutics is a precision medicine company focused on developing novel small molecule therapeutics aimed at treating life-threatening diseases with significant unmet clinical needs. The company is dedicated to innovation and excellence, leveraging targeted protein degradation to create breakthrough solutions that effectively target disease-generating proteins. With a growing pipeline of therapeutics, Beactica is committed to advancing life-saving treatments into clinical settings for patients in need. They also offer compelling investment opportunities, supported by their successful drug development technology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beactica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Beactica had a recent Job posting/layoffs
Check out if Beactica is spiking on competitors!
Earning: See what the market has to say on Beactica recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Beactica
Product Launch: Get notified when Beactica launches new products
Funding: Get notified immidiatlly once Beactica has new funding data
Check if Beactica has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Beactica, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Beactica
Find more new buyers
Company Profile Activity
Activity Insights
Beactica is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Beactica is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Beactica.
Beactica Tech Stack
A closer look at the technologies used by Beactica
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
New Hire
Management Move
Peter Brandt has been named Head of Chemistry. Previously, Brandt served as Principal Scientist at AstraZeneca.
Funding
Telecom, Pain Point
Funding
Beactica News & Media
Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
UPPSALA, Sweden, Oct. 7, 2025 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision medicine company, today announced that it has conducted a first scientific advisory meeting with the Swedish Medical Products Agency regarding the drug candidate BEA-17. Specifically, the...Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
UPPSALA, Sweden, Oct. 7, 2025 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision medicine company, today announced that it has conducted a first scientific advisory meeting with the Swedish Medical Products Agency regarding the drug candidate BEA-17. Specifically, the...Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024
Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024. The conference will take place on April 5–10, 2024 in San Diego, California. Dr Peter Brandt, Head of Chemistry, will present a poster entitled Degraders of TEAD transcription factors based on interface 3 binders on Sunday April 7, 2024, at 1:30 PM – 5:00Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences
STOCKHOLM, Sept. 26, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beactica
Sign Up For FreeTo access detailed company insights
Beactica Therapeutics is a precision medicine company focused on developing novel small molecule therapeutics aimed at treating life-threatening diseases with significant unmet clinical needs. The company is dedicated to innovation and excellence, leveraging targeted protein degradation to create breakthrough solutions that effectively target disea... Read More
